NOT KNOWN DETAILS ABOUT SEVITERONEL

-mutated tumors. Nevertheless, merely a portion of such individuals responds to immune checkpoint or PARP inhibitors and in many cases individuals who do answer frequently produce resistance and relapse.Mechanistically, we report differential binding of AR to target genes from the existence of enzalutamide and seviteronel, suggesting various mechan